Ketamine for Pain in Adults and Children with Cancer: A Systematic Review and Synthesis of the Literature

Pain Medicine (United States)

Volumn 14, Issue 10, 2013, Pages 1505-1517

  Bredlau, Amy Lee ^a   Thakur, Rajbala ^b   Korones, David Nathan ^c   Dworkin, Robert H ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Adverse Events; Cancer Pain; Children; Chronic Pain; Ketamine; Pediatric

Indexed keywords

BENZODIAZEPINE; DIPYRONE; GLYCERYL TRINITRATE; KETAMINE; LIDOCAINE; MIDAZOLAM; MORPHINE; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SODIUM CHLORIDE;

ABDOMINAL PAIN; ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; AGITATION; ANOREXIA; ANXIETY DISORDER; BLADDER CANCER; BLURRED VISION; BONE CANCER; CANCER OF UNKNOWN PRIMARY SITE; CANCER PAIN; CHILDHOOD CANCER; COLON CANCER; COLORECTAL CANCER; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CYSTITIS; DELIRIUM; DEPERSONALIZATION; DIGESTIVE SYSTEM CANCER; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSURIA; ELEVATED BLOOD PRESSURE; EWING SARCOMA; FATIGUE; GLIOBLASTOMA; GYNECOLOGIC CANCER; HALLUCINATION; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOXIA; INJECTION SITE REACTION; INSOMNIA; KIDNEY CANCER; LARYNX SPASM; LIVER CANCER; LIVER FAILURE; LUNG CANCER; MEMORY DISORDER; MOOD DISORDER; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MYELODYSPLASTIC SYNDROME; MYOCLONUS; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROTOXICITY; NIGHTMARE; NONHUMAN; NYSTAGMUS; OROPHARYNX CANCER; OSTEOSARCOMA; PANCREAS CANCER; PROSTATE CANCER; PRURITUS; RECTUM CANCER; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOFT TISSUE CANCER; SOMNOLENCE; SPEECH DISORDER; SPINDLE CELL SARCOMA; STOMACH CANCER; SYNOVIAL SARCOMA; THOUGHT DISORDER; URINE RETENTION; UTERINE CERVIX CANCER; UTERUS CANCER; VERTIGO; VOMITING;

ADVERSE EVENTS; CANCER PAIN; CHILDREN; CHRONIC PAIN; KETAMINE; PEDIATRIC;

ADULT; ANALGESICS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; KETAMINE; NEOPLASMS; PAIN MANAGEMENT; PAIN, INTRACTABLE;

EID: 84885853370     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12182     Document Type: Review

References (67)

1. Vissers KC, Besse K, Wagemans M, etal. 23. Pain in patients with cancer. Pain Pract 2011;11(5):453-475.
2. Reich DL, Silvay G. Ketamine: An update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36(2):186-197.
3. Mehta AK, Halder S, Khanna N, Tandon OP, Sharma KK. Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: Role of opioid and N-methyl-D-aspartate receptors. Hum Exp Toxicol 2012;31(1):51-56.
4. Romero TR, Galdino GS, Silva GC, etal. Ketamine activates the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats. Anesth Analg 2011;113(5):1254-1259.
5. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated signaling by ketamine. J Neurochem 2011;119(2):294-302.
6. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 2003;26(3):867-875.
7. Bell RF. Ketamine for chronic non-cancer pain. Pain 2009;141(3):210-214.
8. Okon T. Ketamine: An introduction for the pain and palliative medicine physician. Pain Physician 2007;10(3):493-500.
9. Arendt-Nielsen L, Mansikka H, Staahl C, etal. A translational study of the effects of ketamine and pregabalin on temporal summation of experimental pain. Reg Anesth Pain Med 2011;36(6):585-591.
10. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10(9):895-926.
11. Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 1984;309(5965):261-263.
12. Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride. Pain 1996;64(2):283-291.
13. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011;152(3 suppl):S2-15.
14. Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: A review. Eur J Pain 2010;14(5):466-472.
15. Liberati A, Altman DG, Tetzlaff J, etal. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 2009;151(4):W65-94.
16. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003;(1):CD003351.
17. Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 1996;43(4):379-383.
18. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999;90(6):1528-1533.
19. Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 1999;11(8):663-668.
20. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20(4):246-252.
21. Hardy J, Quinn S, Fazekas B, etal. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30(29):3611-3617.
22. Jackson K, Ashby M, Martin P, etal. "Burst" ketamine for refractory cancer pain: An open-label audit of 39 patients. J Pain Symptom Manage 2001;22(4):834-842.
23. Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002;23(1):60-65.
24. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005;13(3):188-193.
25. Sigtermans MJ, van Hilten JJ, Bauer MC, etal. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 2009;145(3):304-311.
26. Schwartzman RJ, Alexander GM, Grothusen JR, etal. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study. Pain 2009;147(1-3):107-115.
27. Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 2007;8(6):515-521.
28. Conway M, White N, Jean CS, Zempsky WT, Steven K. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Oncol Nurs 2009;26(2):100-106.
29. Tsui BC, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol 2004;26(10):678-680.
30. Ugur F, Gulcu N, Boyaci A. Oral ketamine for pain relief in a child with abdominal malignancy. Pain Med 2009;10(1):120-121.
31. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m and oral ketamine. Br J Anaesth 1981;53(8):805-810.
32. Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 1997;41(3):427-429.
33. Barton DL, Wos EJ, Qin R, etal. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011;19(6):833-841.
34. Ushida T, Tani T, Kanbara T, etal. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. Reg Anesth Pain Med 2002;27(5):524-528.
35. Huge V, Lauchart M, Magerl W, etal. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 2010;14(4):387-394.
36. Ryan AJ, Lin F, Atayee RS. Ketamine mouthwash for mucositis pain. J Palliat Med 2009;12(11):989-991.
37. Shrestha SK, Bhattarai B, Singh J. Ketamine gargling and postoperative sore throat. JNMA J Nepal Med Assoc 2010;50(180):282-285.
38. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005;30(5):485-491.
39. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother 2006;60(7):341-348.
40. Noppers IM, Niesters M, Aarts LP, etal. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases. Pain 2011;152(9):2173-2178.
41. aan het Rot M, Collins KA, Murrough JW, etal. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67(2):139-145.
42. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14(8):1127-1131.
43. Nagels A, Kirner-Veselinovic A, Krach S, Kircher T. Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency. Neuroimage 2011;54(2):1307-1314.
44. Krystal JH, Karper LP, Seibyl JP, etal. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51(3):199-214.
45. Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for the management of neuropathic cancer pain. Pain 2005;117(1-2):231-235.
46. Karpinski N, Dunn J, Hansen L, Masliah E. Subpial vacuolar myelopathy after intrathecal ketamine: Report of a case. Pain 1997;73(1):103-105.
47. Braun S, Gaza N, Werdehausen R, etal. Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells. Br J Anaesth 2010;105(3):347-354.
48. Ben-Ari A, Lewis MC, Davidson E. Chronic administration of ketamine for analgesia. J Pain Palliat Care Pharmacother 2007;21(1):7-14.
49. Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol 2001;23(9):616-619.
50. Anderson BJ, Palmer GM. Recent developments in the pharmacological management of pain in children. Curr Opin Anaesthesiol 2006;19(3):285-292.
51. Bredlau AL, McDermott MP, Adam HR, etal. Oral ketamine for children with chronic pain: A pilot phase 1 study. J Pediatr 2013;163(1):194-200.
52. Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatr Emerg Care 2009;25(5):325-328.
53. Capape S, Mora E, Mintegui S, etal. Prolonged sedation and airway complications after administration of an inadvertent ketamine overdose in emergency department. Eur J Emerg Med 2008;15(2):92-94.
54. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: A new clinical entity. Urology 2007;69(5):810-812.
55. Gregoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B etal. Ketamine-associated ulcerative cystitis: A new clinical entity. Urology 69: 810-812, 2007). Urology 2008;71(6):1232-1233.
56. Green SM, Cote CJ. Ketamine and neurotoxicity: Clinical perspectives and implications for emergency medicine. Ann Emerg Med 2009;54(2):181-190.
57. Wilder RT, Flick RP, Sprung J, etal. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology 2009;110(4):796-804.
58. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012;(11):CD003351.
59. Borsook D. Ketamine and chronic pain-Going the distance. Pain 2009;145(3):271-272.
60. Hagelberg NM, Peltoniemi MA, Saari TI, etal. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010;14(6):625-629.
61. Trujillo KA, Zamora JJ, Warmoth KP. Increased response to ketamine following treatment at long intervals: Implications for intermittent use. Biol Psychiatry 2008;63(2):178-183.
62. Curran HV, Monaghan L. In and out of the K-hole: A comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001;96(5):749-760.
63. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction 2000;95(5):687-695.
64. Jaeschke R, Guyatt GH, Dellinger P, etal. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744.
65. Benitez-Rosario MA, Salinas-Martin A, Gonzalez-Guillermo T, Feria M. A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: Effect of a 1:1 ratio. J Pain Symptom Manage 2011;41(6):1098-1105.
66. Jackson K, Ashby M, Howell D, etal. The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study. J Palliat Care 2010;26(3):176-183.
67. Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: Development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 2005;8(1):49-57.